Last $13.90 USD
Change Today 0.00 / 0.00%
Volume 0.0
HZNP On Other Exchanges
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma inc (HZNP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $18.30
52 Week Low
08/21/13 - $2.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HORIZON PHARMA INC (HZNP)

horizon pharma inc (HZNP) Related Businessweek News

No Related Businessweek News Found

horizon pharma inc (HZNP) Details

Horizon Pharma, Inc., a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. Its products include DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA and ankylosing spondylitis (AS). The company also offers RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. Horizon Pharma, Inc. was founded in 2005 and is headquartered in Deerfield, Illinois.

427 Employees
Last Reported Date: 05/9/14
Founded in 2005

horizon pharma inc (HZNP) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $589.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $374.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.

horizon pharma inc (HZNP) Key Developments

Horizon Pharma Inc. Announces Execution of $300 Million Senior Secured Credit Agreement

Horizon Pharma, Inc. announced that it has entered into an agreement with a group of lenders to provide Horizon with $300 million in financing through a five year senior secured credit facility. Funding is expected to occur coincident with the closing of the proposed acquisition of Vidara Therapeutics International Ltd. This agreement replaces the $250 million bridge loan commitment received from Deerfield Management Company, L.P. The company intends to use proceeds to effect the proposed acquisition of Vidara, pay related transaction fees and expenses and for general corporate purposes. Citigroup Global Markets Inc. and Cowen and Company, LLC and their respective affiliates are acting as joint lead arrangers and initial lenders to Horizon for the financing.

Horizon Pharma, Inc. Announces Management Changes

Horizon Pharma, Inc. announced that Robert J. De Vaere, its current Chief Financial Officer, will retire on September 30, 2014. The company has also named Paul W. Hoelscher as Executive Vice President, Finance, effective from June 23, 2014 and its Chief Financial Officer, effective October 1, 2014. At the time of his retirement, Mr. De Vaere will enter into a one-year consulting agreement with the company to support the ongoing integration of Vidara following the closing of the acquisition and to provide general business support and guidance as the company seeks to continue its recent growth, both organically and through acquisition. Mr. Hoelscher joins Horizon from OfficeMax, Inc. where he was most recently Senior Vice President, Finance and was co-lead in integration planning activities related to its recent merger with Office Depot.

Horizon Pharma, Inc. Presents at BIO International Convention, Jun-25-2014 10:00 AM

Horizon Pharma, Inc. Presents at BIO International Convention, Jun-25-2014 10:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $10.05 USD -3.85

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $11.74 USD 0.00
Pfizer Inc $30.19 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at